Jevtana Delays Disease Progression, Prolongs Survival in Men with mCRPC, Phase 4 Trial Shows

Jevtana Delays Disease Progression, Prolongs Survival in Men with mCRPC, Phase 4 Trial Shows
The chemotherapy agent Jevtana (cabazitaxel) is better than a second course of androgen receptor inhibitors at delaying disease progression and prolonging survival among men with metastatic castration-resistant prostate cancer (mCRPC), a Phase 4 trial shows. All of the participants had seen their disease progress while previously receiving androgen receptor-targeted agent therapy and docetaxel. The trial’s findings were shared in a late-breaking presentation, titled "CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)," at the European Society for Medical Oncology (ESMO) 2019 Congress, held Sept. 27 to Oct. 1 in Barcelona, Spain. The results also were simultaneously published in The New England Journal of Medicine. Jevtana is a chemotherapy agent marketed by Sanofi Genzyme now used to treat men with advanced forms of prostate cancer. The effects of Jevtana in combination with
Subscribe or to access all post and page content.